bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Authors: Weiss Glen J. , Infante Jeffrey R. , Chiorean E. Gabriela , Borad Mitesh J. , Bendell Johanna C. , Molina Julian R. , Tibes Raoul , Ramanathan Ramesh K. , Lewandowski Karen , Jones Suzanne F. , Lacouture Mario E. , Langmuir Virginia K. , Lee Hank , Kroll Stew , Burris Howard A.
Published: April 2023

Abstract
Purpose: The objectives of this phase 1, first-in-human study were to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics, and preliminary activity of the hypoxia-activated prodrug TH-302 in patients with advanced solid tumors.

Experimental Design: TH-302 was administered intravenously over 30 to 60 minutes in two regimens: three times weekly dosing followed by 1 week off (arm A) and every 3-week dosing (arm B).

Results: Fifty-seven patients enrolled (arm A: N = 37 and arm B: N = 20). The TH-302 dose was escalated from 7.5 to 670 mg/m2 in arm A and from 670 to 940 mg/m2 in arm B. The most common adverse events were nausea, skin rash, fatigue, and vomiting. Hematologic toxicity was mild and limited. Grade 3 skin and mucosal toxicities were dose limiting at 670 mg/m2 in arm A; the MTD was 575 mg/m2. In arm B, grade 3 fatigue and grade 3 vaginitis/proctitis were dose limiting at 940 mg/m2; the MTD was 670 mg/m2. Plasma concentrations of TH-302 and the active metabolite Br-IPM (brominated version of isophosphoramide mustard) increased proportionally with dose. Two partial responses were noted in patients with metastatic small cell lung cancer (SCLC) and melanoma in arm A at 480 and 670 mg/m2. Stable disease was observed in arms A and B in 18 and 9 patients, respectively.

Conclusions: The MTD of TH-302 was 575 mg/m2 weekly and 670 mg/m2 every 3 weeks. Skin and mucosal toxicities were DLTs. On the basis of responses in metastatic melanoma and SCLC, further investigations in these indications were initiated. Clin Cancer Res; 17(9); 2997–3004. ©2011 AACR.
Data from Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression
Authors: Hatam Lynda J. , DeVoti James A. , Rosenthal David W. , Lam Fung , Abramson Allan L. , Steinberg Bettie M. , Bonagura Vincent R.
Published: April 2023

Abstract
Purpose: Respiratory papillomas, caused by human papillomaviruses types 6 and 11 (HPV6/11), are premalignant lesions with potential for malignant conversion. The cytokine and chemokine micromilieu of papillomas is TH2-like with a marked absence of IFN-γ expression. To illuminate why patients with recurrent respiratory papillomatosis (RRP) fail to effectively control their disease, we further investigated the suppressive cellular microenvironment in papillomas.

Experimental Design: CD4+CD25+CD127low/−Foxp3+ regulatory T cells (Treg) and CD4+CD25−CD127low/−Foxp3− T cells within papillomas were characterized and isolated. Their suppressor function was measured by inhibition of peripheral blood mononuclear cell (PBMC) proliferation. Expression of PD-1, CD69, and Helios was identified on these T cells. PD-L1, PD-L2, CCL17, and CCL22 mRNA was also identified in papillomas by quantitative PCR.

Results: Functional Tregs were markedly enriched in papillomas and strongly inhibited anti-CD3 and anti-CD28 antibody activated PBMC proliferation. The natural Treg marker Helios was reduced on Tregs from papillomas, indicating that the majority of Tregs in papillomas are adaptive. The majority of the papilloma-derived CD4+ T cells expressed the CD4+CD25−CD127low/−Foxp3−PD1+CD69+ phenotype and failed to suppress PBMC proliferation, suggesting that they are chronically activated and exhausted. The Treg-attracting chemokine CCL22 was equally expressed by all laryngeal tissues examined. However, CCL17 was robustly expressed by papillomas compared with unaffected laryngeal tissues from RRP patients and individuals without RRP. PD-L1 was elevated in papillomas compared with control laryngeal tissues.

Conclusions: Papilloma CD4+ T cells are enriched with functional Tregs, and the adaptive Helios− Treg fraction was increased within the TH2-like papilloma micromilieu. CD4+CD25−CD127low/−Foxp3− T-cells failed to suppress PBMC proliferation and may be exhausted. The PD-1/PDL-1 pathway may represent an additional immunosuppressive mechanism that contributes to defective HPV6/11 clearance in RRP. Clin Cancer Res; 18(7); 1925–35. ©2012 AACR.
Data from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Authors: Li Yuhuan , Wang Li-Xin , Pang Puiyi , Cui Zhihua , Aung Sandra , Haley Daniel , Fox Bernard A. , Urba Walter J. , Hu Hong-Ming
Published: April 2023

Abstract
Purpose: We previously reported that autophagy in tumor cells plays a critical role in cross-presentation of tumor antigens and that autophagosomes are efficient antigen carriers for cross-priming of tumor-reactive CD8+ T cells. Here, we sought to characterize further the autophagosome-enriched vaccine named DRibble (DRiPs-containing blebs), which is derived from tumor cells after inhibition of protein degradation, and to provide insights into the mechanisms responsible for their efficacy as a novel cancer immunotherapy.

Experimental Design: DRibbles were characterized by Western blot and light or transmission electron microscopy. The efficiency of cross-presentation mediated by DRibbles was first compared with that of whole-tumor cells and pure proteins. The mechanisms of antigen cross-presentation by DRibbles were analyzed, and the antitumor efficacy of the DRibble vaccine was tested in 3LL Lewis lung tumors and B16F10 melanoma.

Results: The DRibbles sequester both long-lived and short-lived proteins, including defective ribosomal products (DRiP), and damage-associated molecular pattern molecules exemplified by HSP90, HSP94, calreticulin, and HMGB1. DRibbles express ligands for CLEC9A, a newly described C-type lectin receptor expressed by a subset of conventional and plasmacytoid dendritic cells (DC), and cross-presentation was partially CLEC9A dependent. Furthermore, this autophagy-assisted antigen cross-presentation pathway involved both caveolae- and clathrin-mediated endocytosis and endoplasmic reticulum–associated degradation machinery. It depends on proteasome and TAP1, but not lysosome functions of antigen-presenting cells. Importantly, DCs loaded with autophagosome-enriched DRibbles can eradicate 3LL Lewis lung tumors and significantly delay the growth of B16F10 melanoma.

Conclusions: These data documented the unique characteristics and potent antitumor efficacy of the autophagosome-based DRibble vaccine. The efficacy of DRibble cancer vaccine will be further tested in clinical trials. Clin Cancer Res; 17(22); 7047–57. ©2011 AACR.
Data from Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma
Authors: Wu Rong , Hu Tom C. , Rehemtulla Alnawaz , Fearon Eric R. , Cho Kathleen R.
Published: April 2023

Abstract
Purpose: Genetically engineered mouse (GEM) models of ovarian cancer that closely recapitulate their human tumor counterparts may be invaluable tools for preclinical testing of novel therapeutics. We studied murine ovarian endometrioid adenocarcinomas (OEA) arising from conditional dysregulation of canonical WNT and PI3K/AKT/mTOR pathway signaling to investigate their response to conventional chemotherapeutic drugs and mTOR or AKT inhibitors.

Experimental Design: OEAs were induced by injection of adenovirus expressing Cre recombinase (AdCre) into the ovarian bursae of Apcflox/flox; Ptenflox/flox mice. Tumor-bearing mice or murine OEA-derived cell lines were treated with cisplatin and paclitaxel, mTOR inhibitor rapamycin, or AKT inhibitors API-2 or perifosine. Treatment effects were monitored in vivo by tumor volume and bioluminescence imaging, in vitro by WST-1 proliferation assays, and in OEA tissues and cells by immunoblotting and immunostaining for levels and phosphorylation status of PI3K/AKT/mTOR signaling pathway components.

Results: Murine OEAs developed within 3 weeks of AdCre injection and were not preceded by endometriosis. OEAs responded to cisplatin + paclitaxel, rapamycin, and AKT inhibitors in vivo. In vitro studies showed that response to mTOR and AKT inhibitors, but not conventional cytotoxic drugs, was dependent on the status of PI3K/AKT/mTOR signaling. AKT inhibition in APC−/Pten− tumor cells resulted in compensatory upregulation of ERK signaling.

Conclusions: The studies show the utility of this GEM model of ovarian cancer for preclinical testing of novel PI3K/AKT/mTOR signaling inhibitors and provide evidence for compensatory signaling, suggesting that multiple rather than single agent targeted therapy will be more efficacious for treating ovarian cancers with activated PI3K/AKT/mTOR signaling. Clin Cancer Res; 17(23); 7359–72. ©2011 AACR.
Data from Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers
Authors: Reinert Thomas , Modin Charlotte , Castano Francisco M. , Lamy Philippe , Wojdacz Tomasz K. , Hansen Lise Lotte , Wiuf Carsten , Borre Michael , Dyrskjøt Lars , Ørntoft Torben F.
Published: April 2023

Abstract
Purpose: Epigenetic alterations are common and can now be addressed in a parallel fashion. We investigated the methylation in bladder cancer with respect to location in genome, consistency, variation in metachronous tumors, impact on transcripts, chromosomal location, and usefulness as urinary markers.

Experimental Design: A microarray assay was utilized to analyze methylation in 56 samples. Independent validation was conducted in 63 samples by a PCR-based method and bisulfite sequencing. The methylation levels in 174 urine specimens were quantified. Transcript levels were analyzed using expression microarrays and pathways were analyzed using dedicated software.

Results: Global methylation patterns were established within and outside CpG islands. We validated methylation of the eight tumor markers genes ZNF154 (P < 0.0001), HOXA9 (P < 0.0001), POU4F2 (P < 0.0001), EOMES (P = 0.0005), ACOT11 (P = 0.0001), PCDHGA12 (P = 0.0001), CA3 (P = 0.0002), and PTGDR (P = 0.0110), the candidate marker of disease progression TBX4 (P < 0.04), and other genes with stage-specific methylation. The methylation of metachronous tumors was stable and targeted to certain pathways. The correlation to expression was not stringent. Chromosome 21 showed most differential methylation (P < 0.0001) and specifically hypomethylation of keratins, which together with keratin-like proteins were epigenetically regulated. In DNA from voided urine, we detected differential methylation of ZNF154 (P < 0.0001), POU4F2 (P < 0.0001), HOXA9 (P < 0.0001), and EOMES (P < 0.0001), achieving 84% sensitivity and 96% specificity.

Conclusions: We initiated a detailed mapping of the methylome in metachronous bladder cancer. Novel genes with tumor, chromosome, as well as pathway-specific differential methylation in bladder cancer were identified. The methylated genes were promising cancer markers for early detection of bladder cancer. Clin Cancer Res; 17(17); 5582–92. ©2011 AACR.
Data from Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I
Authors: Sippel Trisha R. , White Jason , Nag Kamalika , Tsvankin Vadim , Klaassen Marci , Kleinschmidt-DeMasters B.K. , Waziri Allen
Published: April 2023

Abstract
Purpose: The source of glioblastoma (GBM)-associated immunosuppression remains multifactorial. We sought to clarify and therapeutically target myeloid cell–derived peripheral immunosuppression in patients with GBM.

Experimental Design: Direct ex vivo T-cell function, serum Arginase I (ArgI) levels, and circulating myeloid lineage populations were compared between patients with GBM and normal donors or patients with other intracranial tumors. Immunofunctional assays were conducted using bulk and sorted cell populations to explore the potential transfer of myeloid cell–mediated immunosuppression and to identify a potential mechanism for these effects. ArgI-mediated immunosuppression was therapeutically targeted in vitro through pharmacologic inhibition or arginine supplementation.

Results: We identified a significantly expanded population of circulating, degranulated neutrophils associated with elevated levels of serum ArgI and decreased T-cell CD3ζ expression within peripheral blood from patients with GBM. Sorted CD11b+ cells from patients with GBM were found to markedly suppress normal donor T-cell function in coculture, and media harvested from mitogen-stimulated GBM peripheral blood mononuclear cell (PBMC) or GBM-associated mixed lymphoid reactions showed ArgI levels that were significantly higher than controls. Critically, T-cell suppression in both settings could be completely reversed through pharmacologic ArgI inhibition or with arginine supplementation.

Conclusions: These data indicate that peripheral cellular immunosuppression in patients with GBM is associated with neutrophil degranulation and elevated levels of circulating ArgI, and that T-cell function can be restored in these individuals by targeting ArgI. These data identify a novel pathway of GBM-mediated suppression of cellular immunity and offer a potential therapeutic window for improving antitumor immunity in affected patients. Clin Cancer Res; 17(22); 6992–7002. ©2011 AACR.
Data from Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment Trials
Authors: An Ming-Wen , Mandrekar Sumithra J. , Branda Megan E. , Hillman Shauna L. , Adjei Alex A. , Pitot Henry C. , Goldberg Richard M. , Sargent Daniel J.
Published: April 2023

Abstract
Purpose: The categorical definition of response assessed via the Response Evaluation Criteria in Solid Tumors has documented limitations. We sought to identify alternative metrics for tumor response that improve prediction of overall survival.

Experimental Design: Individual patient data from three North Central Cancer Treatment Group trials (N0026, n = 117; N9741, n = 1,109; and N9841, n = 332) were used. Continuous metrics of tumor size based on longitudinal tumor measurements were considered in addition to a trichotomized response [TriTR: response (complete or partial) vs. stable disease vs. progression). Cox proportional hazards models, adjusted for treatment arm and baseline tumor burden, were used to assess the impact of the metrics on subsequent overall survival, using a landmark analysis approach at 12, 16, and 24 weeks postbaseline. Model discrimination was evaluated by the concordance (c) index.

Results: The overall best response rates for the three trials were 26%, 45%, and 25%, respectively. Although nearly all metrics were statistically significantly associated with overall survival at the different landmark time points, the concordance indices (c-index) for the traditional response metrics ranged from 0.59 to 0.65; for the continuous metrics from 0.60 to 0.66; and for the TriTR metrics from 0.64 to 0.69. The c-indices for TriTR at 12 weeks were comparable with those at 16 and 24 weeks.

Conclusions: Continuous tumor measurement–based metrics provided no predictive improvement over traditional response–based metrics or TriTR; TriTR had better predictive ability than best TriTR or confirmed response. If confirmed, TriTR represents a promising endpoint for future phase II trials. Clin Cancer Res; 17(20); 6592–9. ©2011 AACR.
Data from LY2109761 Attenuates Radiation-Induced Pulmonary Murine Fibrosis via Reversal of TGF-β and BMP-Associated Proinflammatory and Proangiogenic Signals
Authors: Flechsig Paul , Dadrich Monika , Bickelhaupt Sebastian , Jenne Jürgen , Hauser Kai , Timke Carmen , Peschke Peter , Hahn Eric W. , Gröne Hermann-Josef , Yingling Jonathan , Lahn Michael , Wirkner Ute , Huber Peter E.
Published: April 2023

Abstract
Purpose: Radiotherapy is used for the treatment of lung cancer, but at the same time induces acute pneumonitis and subsequent pulmonary fibrosis, where TGF-β signaling is considered to play an important role.

Experimental Design: We irradiated thoraces of C57BL/6 mice (single dose, 20 Gy) and administered them a novel small-molecule TGF-β receptor I serine/threonine kinase inhibitor (LY2109761) orally for 4 weeks before, during, or after radiation. Noninvasive lung imaging including volume computed tomography (VCT) and MRI was conducted 6, 16, and 20 weeks after irradiation and was correlated to histologic findings. Expression profiling analysis and protein analysis was conducted in human primary fibroblasts.

Results: Radiation alone induced acute pulmonary inflammation and lung fibrosis after 16 weeks associated with reduced life span. VCT, MRI, and histology showed that LY2109761 markedly reduced inflammation and pulmonary fibrosis resulting in prolonged survival. Mechanistically, we found that LY2109761 reduced p-SMAD2 and p-SMAD1 expression, and transcriptomics revealed that LY2109761 suppressed expression of genes involved in canonical and noncanonical TGF-β signaling and downstream signaling of bone morphogenetic proteins (BMP). LY2109761 also suppressed radiation-induced inflammatory [e.g., interleukin (IL)-6, IL-7R, IL-8] and proangiogenic genes (e.g., ID1) indicating that LY2109761 achieves its antifibrotic effect by suppressing radiation-induced proinflammatory, proangiogenic, and profibrotic signals.

Conclusion: Small-molecule inhibitors of the TGF-β receptor I kinase may offer a promising approach to treat or attenuate radiation-induced lung toxicity or other diseases associated with fibrosis. Clin Cancer Res; 18(13); 3616–27. ©2012 AACR.
Data from Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Authors: Galanis Evanthia , Anderson S. Keith , Lafky Jackie M. , Uhm Joon H. , Giannini Caterina , Kumar Shaji K. , Kimlinger Teresa K. , Northfelt Donald W. , Flynn Patrick J. , Jaeckle Kurt A. , Kaufmann Timothy J. , Buckner Jan C.
Published: April 2023

Abstract
Purpose: We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect. We also investigated whether VEGF, VEGFR2 and hypoxia-inducible factor-1α single-nucleotide polymorphisms (SNP), circulating biomarkers of angiogenesis, and MRI markers such as apparent diffusion coefficient (ADC) are correlated with treatment efficacy and/or toxicity.

Experimental Design: Patients received bevacizumab (5 mg/kg every 2 weeks) with sorafenib (200 mg twice a day, weekly, days 1–5; group A). Due to toxicity, the starting sorafenib dose was subsequently modified to 200 mg every day (group B).

Results: Fifty-four patients were enrolled: 19 patients in group A and 35 in group B. Objective response rate was 18.5% with median duration of 6.7 months (range 0.5–24.1 months). Six-month progression-free survival (PFS6) was 20.4% (11/54), and median overall survival (OS) was 5.6 months [95% confidence interval (CI), 4.7–8.2]; outcome was similar between the two dose groups. We identified SNPs in the VEGF and VEGFR2 promoter regions, which were associated with PFS6 (P < 0.022). Among molecular markers of angiogenesis, a higher log2 baseline level of stromal cell–derived factor-1 was associated with PFS6 success (P = 0.04). Circulating endothelial cells decreased during treatment with subsequent increase at disease progression (P = 0.022). Imaging analysis showed a trend associating ADC-L with poor outcome.

Conclusions: The bevacizumab/sorafenib combination did not improve outcome of patients with recurrent glioblastoma versus historic bevacizumab-treated controls. Biologic markers of response and resistance to bevacizumab in gliomas were identified which merit prospective validation. Clin Cancer Res; 19(17); 4816–23. ©2013 AACR.
Supplementary Fig. S3 from Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
Authors: Afshar Sepideh , Asai Tsuneaki , Morrison Sherie L.
Published: April 2023

Supplementary Fig. S3 from Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer
Supplementary Table S1 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Authors: Bataller Marc , Méndez Carmen , Salas José A. , Portugal José
Published: April 2023

Supplementary Table S1 from Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Supplementary Table 3 from Global microRNA Analysis of the NCI-60 Cancer Cell Panel
Authors: Søkilde Rolf , Kaczkowski Bogumil , Podolska Agnieszka , Cirera Susanna , Gorodkin Jan , Møller Søren , Litman Thomas
Published: April 2023

Supplementary Table 3 from Global microRNA Analysis of the NCI-60 Cancer Cell Panel
Supplementary Figure Legends from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Authors: Ding Yan , Boguslawski Elissa A. , Berghuis Bree D. , Young John J. , Zhang Zhongfa , Hardy Kim , Furge Kyle , Kort Eric , Frankel Arthur E. , Hay Rick V. , Resau James H. , Duesbery Nicholas S.
Published: April 2023

Supplementary Figure Legends from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Supplementary Fig. S5 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Authors: Ding Yan , Boguslawski Elissa A. , Berghuis Bree D. , Young John J. , Zhang Zhongfa , Hardy Kim , Furge Kyle , Kort Eric , Frankel Arthur E. , Hay Rick V. , Resau James H. , Duesbery Nicholas S.
Published: April 2023

Supplementary Fig. S5 from Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma
Supplementary Table S1 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
Authors: An Feng , Drummond Daryl C. , Wilson Shannon , Kirpotin Dmitri B. , Nishimura Stephen L. , Broaddus V. Courtney , Liu Bin
Published: April 2023

Supplementary Table S1 from Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
Supplementary Fig. S1 from Antitumor effect of dsRNA-induced p21WAF1/CIP1 gene activation in human bladder cancer cells
Authors: Chen Zhong , Place Robert F. , Jia Zhe-Jun , Pookot Deepa , Dahiya Rajvir , Li Long-Cheng
Published: April 2023

Supplementary Fig. S1 from Antitumor effect of dsRNA-induced p21WAF1/CIP1 gene activation in human bladder cancer cells
Supplementary Table S1 from Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors
Authors: Goto Yasufumi , Arigami Takaaki , Kitago Minoru , Nguyen Sandy L. , Narita Norihiko , Ferrone Soldano , Morton Donald L. , Irie Reiko F. , Hoon Dave S.B.
Published: April 2023

Supplementary Table S1 from Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors
Supplementary Fig. from Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
Authors: Rosato Roberto R. , Almenara Jorge A. , Maggio Sonia C. , Coe Stefanie , Atadja Peter , Dent Paul , Grant Steven
Published: April 2023

Supplementary Fig. from Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
Supplementary Table 1, Supplementary Figures 1-4 from ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
Authors: Fletcher Graham C. , Brokx Richard D. , Denny Trisha A. , Hembrough Todd A. , Plum Stacy M. , Fogler William E. , Sidor Carolyn F. , Bray Mark R.
Published: April 2023

Supplementary Table 1, Supplementary Figures 1-4 from ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action
Supplementary Table S4 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Authors: Ross-Macdonald Petra , de Silva Heshani , Guo Qi , Xiao Hong , Hung Chen-Yi , Penhallow Becky , Markwalder Jay , He Liqi , Attar Ricardo M. , Lin Tai-an , Seitz Steven , Tilford Charles , Wardwell-Swanson Judith , Jackson Donald
Published: April 2023

Supplementary Table S4 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Supplementary Table S3 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Authors: Ross-Macdonald Petra , de Silva Heshani , Guo Qi , Xiao Hong , Hung Chen-Yi , Penhallow Becky , Markwalder Jay , He Liqi , Attar Ricardo M. , Lin Tai-an , Seitz Steven , Tilford Charles , Wardwell-Swanson Judith , Jackson Donald
Published: April 2023

Supplementary Table S3 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Supplementary Table S1 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Authors: Ross-Macdonald Petra , de Silva Heshani , Guo Qi , Xiao Hong , Hung Chen-Yi , Penhallow Becky , Markwalder Jay , He Liqi , Attar Ricardo M. , Lin Tai-an , Seitz Steven , Tilford Charles , Wardwell-Swanson Judith , Jackson Donald
Published: April 2023

Supplementary Table S1 from Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Supplementary Table 1 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas
Authors: Hu Kaiji , Lee Cathy , Qiu Dexin , Fotovati Abbas , Davies Alastair , Abu-Ali Samah , Wai Daniel , Lawlor Elizabeth R. , Triche Timothy J. , Pallen Catherine J. , Dunn Sandra E.
Published: April 2023

Supplementary Table 1 from Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas
Supplementary Fig. S1 from Arsenic trioxide decreases AKT protein in a caspase-dependent manner
Authors: Mann Koren K. , Colombo Myrian , Miller Wilson H.
Published: April 2023

Supplementary Fig. S1 from Arsenic trioxide decreases AKT protein in a caspase-dependent manner
Supplemental Figure 1 from Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
Authors: Grosso Sébastien , Puissant Alexandre , Dufies Maeva , Colosetti Pascal , Jacquel Arnaud , Lebrigand Kevin , Barbry Pascal , Deckert Marcel , Cassuto Jill Patrice , Mari Bernard , Auberger Patrick
Published: April 2023

Legend to supplemental Figure 1: Ingenuity Pathway Analysis identifies a network of genes upregulated in both resistant clones compared to parental cells. The network is displayed graphically as nodes (genes/gene products) and edges (the biological relationships between the nodes). All grey nodes correspond to up-regulated genes in both IM-R and PD-R resistant cells. As described in the legend provided, nodes are displayed using various shapes that represent the functional class of the gene product. Edges are displayed with various labels that describe the nature of the relationship between the nodes (A, activation; B, binding; E, expression; I, inhibition; P, phosphorylation; T, transcription). Edges without a label represent binding only. White nodes were identified by the pathway analysis as part of the network.
Supplementary Data from Phospholipase A2 Activity of Peroxiredoxin 6 Promotes Invasion and Metastasis of Lung Cancer Cells
Authors: Ho Jin-Nyoung , Lee Seung Bum , Lee Seung-Sook , Yoon Sung Hwan , Kang Ga Young , Hwang Sang-Gu , Um Hong-Duck
Published: April 2023

Supplementary Data from Phospholipase A2 Activity of Peroxiredoxin 6 Promotes Invasion and Metastasis of Lung Cancer Cells
Supplementary Figure 1 from Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs
Authors: Preston Thomas J. , Henderson Jeffrey T. , McCallum Gordon P. , Wells Peter G.
Published: April 2023

Supplementary Figure 1 from Base excision repair of reactive oxygen species–initiated 7,8-dihydro-8-oxo-2′-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs
Supplemental Table S1 from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Authors: Qian Xiaozhong , LaRochelle William J. , Ara Gulshan , Wu Frank , Petersen Kamille Dumong , Thougaard Annemette , Sehested Maxwell , Lichenstein Henri S. , Jeffers Michael
Published: April 2023

Supplemental Table S1 from Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Supplementary Figures 1-2 from Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death
Authors: Pritchard Justin R. , Cosgrove Benjamin D. , Hemann Michael T. , Griffith Linda G. , Wands Jack R. , Lauffenburger Douglas A.
Published: April 2023

Supplementary Figures 1-2 from Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death
Supplementary Data from Prostate-derived factor—a novel inhibitor of drug-induced cell death in colon cancer cells
Authors: Proutski Irina , Stevenson Leanne , Allen Wendy L. , McCulla Andrea , Boyer John , McLean Estelle G. , Longley Daniel B. , Johnston Patrick G.
Published: April 2023

Supplementary Data from Prostate-derived factor—a novel inhibitor of drug-induced cell death in colon cancer cells
Supplementary Fig. from WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells
Authors: Tang Yaxiong , Simoneau Anne R. , Liao Wu-xiang , Yi Guo , Hope Christopher , Liu Feng , Li Shunqiang , Xie Jun , Holcombe Randall F. , Jurnak Frances A. , Mercola Dan , Hoang Bang H. , Zi Xiaolin
Published: April 2023

Supplementary Fig. from WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells
Supplementary Figure Legends 1-2 from Molecular Evolutionary Analysis of Cancer Cell Lines
Authors: Zhang Yan , Italia Michael J. , Auger Kurt R. , Halsey Wendy S. , Van Horn Stephanie F. , Sathe Ganesh M. , Magid-Slav Michal , Brown James R. , Holbrook Joanna D.
Published: April 2023

Supplementary Figure Legends 1-2 from Molecular Evolutionary Analysis of Cancer Cell Lines
Supplementary Table S1 from Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
Authors: Sørlie Therese , Perou Charles M. , Fan Cheng , Geisler Stephanie , Aas Turid , Nobel Andrew , Anker Gun , Akslen Lars A. , Botstein David , Børresen-Dale Anne-Lise , Lønning Per Eystein
Published: April 2023

Supplementary Table S1 from Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
Supplementary Figure 1 from Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment
Authors: Liu Shuang , Qi Yanfeng , Ge Yubin , Duplessis Tamika , Rowan Brian G. , Ip Clement , Cheng Helen , Rennie Paul S. , Horikawa Izumi , Lustig Arthur J. , Yu Qun , Zhang Haitao , Dong Yan
Published: April 2023

Supplementary Figure 1 from Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment
Supplementary Table 1 from Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines
Authors: Holbeck Susan L. , Collins Jerry M. , Doroshow James H.
Published: April 2023

Supplementary Table 1 from Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines
Supplementary Fig. from MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism
Authors: Park Margaret A. , Walker Teneille , Martin Aditi Pandya , Allegood Jeremy , Vozhilla Nicollaq , Emdad Luni , Sarkar Devanand , Rahmani Mohammed , Graf Martin , Yacoub Adly , Koumenis Costas , Spiegel Sarah , Curiel David T. , Voelkel-Johnson Christina , Grant Steven , Fisher Paul B. , Dent Paul
Published: April 2023

Supplementary Fig. from MDA-7/IL-24–induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK–dependent mechanism
Supplementary Materials and Methods, Supplementary Figure 1 and Supplementary Tables 1 and 2 from Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma
Authors: Bradshaw-Pierce Erica L. , Steinhauer Courtney A. , Raben David , Gustafson Daniel L.
Published: April 2023

PDF - 80KB, Figure S1. Schematic representation of a PBPK model for docetaxel with IP administration. Table S1. Mouse Organ Weight Parameters Table S2. PBPK Model Parameters
Supplementary Fig. S1 from Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
Authors: McGovern Ursula B. , Francis Richard E. , Peck Barrie , Guest Stephanie K. , Wang Jun , Myatt Stephen S. , Krol Janna , Kwok Jimmy M-M. , Polychronis Andreas , Coombes R. Charles , Lam Eric W-F.
Published: April 2023

Supplementary Fig. S1 from Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer
Supplementary Figure 1 from Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma
Authors: Spannuth Whitney A. , Mangala Lingegowda S. , Stone Rebecca L. , Carroll Amy R. , Nishimura Masato , Shahzad Mian M.K. , Lee Sun-Joo , Moreno-Smith Myrthala , Nick Alpa M. , Liu Ren , Jennings Nicholas B. , Lin Yvonne G. , Merritt William M. , Coleman Robert L. , Vivas-Mejia Pablo E. , Zhou Yue , Krasnoperov Valery , Lopez-Berestein Gabriel , Gill Parkash S. , Sood Anil K.
Published: April 2023

Supplementary Figure 1 from Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma
Supplementary Figure 1 from Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
Authors: Nagaraj Nagathihalli S. , Smith J. Joshua , Revetta Frank , Washington M. Kay , Merchant Nipun B.
Published: April 2023

Supplementary Figure 1 from Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
Supplementary Figure 2 from Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
Authors: Bruzzese Francesca , Rocco Monia , Castelli Silvia , Di Gennaro Elena , Desideri Alessandro , Budillon Alfredo
Published: April 2023

Supplementary Figure 2 from Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis
Supplementary Figure 1 from A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts
Authors: Wang Yaolin , Lipari Philip , Wang Xiaoying , Hailey Judith , Liang Lianzhu , Ramos Robert , Liu Ming , Pachter Jonathan A. , Bishop W. Robert , Wang Yan
Published: April 2023

Supplementary Figure 1 from A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts
Supplementary Materials from Silibinin inhibits translation initiation: implications for anticancer therapy
Authors: Lin Chen-Ju , Sukarieh Rami , Pelletier Jerry
Published: April 2023

Supplementary Materials from Silibinin inhibits translation initiation: implications for anticancer therapy
Supplementary Table from Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8
Authors: Wang Daqing , Precopio Melissa , Lan Tao , Yu Dong , Tang Jimmy X. , Kandimalla Ekambar R. , Agrawal Sudhir
Published: April 2023

Supplementary Table from Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8
Supplementary Figure Legend from Human Mutations That Confer Paclitaxel Resistance
Authors: Yin Shanghua , Bhattacharya Rajat , Cabral Fernando
Published: April 2023

Supplementary Figure Legend from Human Mutations That Confer Paclitaxel Resistance
Supplementary Fig. S3 from Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer
Authors: Agarwal Anika , Covic Lidija , Sevigny Leila M. , Kaneider Nicole C. , Lazarides Katherine , Azabdaftari Gissou , Sharifi Sheida , Kuliopulos Athan
Published: April 2023

Supplementary Fig. S3 from Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer
Supplementary Data 1 from Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment
Authors: Ragusa Marco , Majorana Alessandra , Statello Luisa , Maugeri Marco , Salito Loredana , Barbagallo Davide , Guglielmino Maria Rosa , Duro Laura R. , Angelica Rosario , Caltabiano Rosario , Biondi Antonio , Di Vita Maria , Privitera Giuseppe , Scalia Marina , Cappellani Alessandro , Vasquez Enrico , Lanzafame Salvatore , Basile Francesco , Di Pietro Cinzia , Purrello Michele
Published: April 2023

Supplementary Data 1 from Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment
Supplementary Figure Legend from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia
Authors: Tunceroglu Ahmet , Matsuda Michiyuki , Birge Raymond B.
Published: April 2023

Supplementary Figure Legend from Real-time Fluorescent Resonance Energy Transfer Analysis to Monitor Drug Resistance in Chronic Myelogenous Leukemia
Supplementary Figure 2 from Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma
Authors: Koomoa Dana-Lynn T. , Borsics Tamas , Feith David J. , Coleman Craig C. , Wallick Christopher J. , Gamper Ivonne , Pegg Anthony E. , Bachmann André S.
Published: April 2023

Supplementary Figure 2 from Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma
Supplementary Fig. from The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel
Authors: Goldblatt Erin M. , Gentry Erin R. , Fox Melanie J. , Gryaznov Sergei M. , Shen Changyu , Herbert Brittney-Shea
Published: April 2023

Supplementary Fig. from The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel
Supplementary Fig. S1 from Effect of autophagy on multiple myeloma cell viability
Authors: Hoang Bao , Benavides Angelica , Shi Yijiang , Frost Patrick , Lichtenstein Alan
Published: April 2023

Supplementary Fig. S1 from Effect of autophagy on multiple myeloma cell viability
Supplementary Fig. from Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Authors: Kim Young H. , Choi Beom K. , Oh Ho S. , Kang Woo J. , Mittler Robert S. , Kwon Byoung S.
Published: April 2023

Supplementary Fig. from Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Supplementary Figure 1 from Overexpression of GRIM-19 in Cancer Cells Suppresses STAT3-Mediated Signal Transduction and Cancer Growth
Authors: Okamoto Takashi , Inozume Takashi , Mitsui Hiroshi , Kanzaki Mirei , Harada Kazutoshi , Shibagaki Naotaka , Shimada Shinji
Published: April 2023

Supplementary Figure 1 from Overexpression of GRIM-19 in Cancer Cells Suppresses STAT3-Mediated Signal Transduction and Cancer Growth
Supplementary Fig. S2 from Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis
Authors: Park Chaehwa , Lee Inkyoung , Kang Won Ki
Published: April 2023

Supplementary Fig. S2 from Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis
Supplementary Fig. S3 from Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Authors: Thress Kenneth , MacIntyre Terry , Wang Haiyun , Whitston Dave , Liu Zhong-Ying , Hoffmann Ethan , Wang Tao , Brown Jeffrey L. , Webster Kevin , Omer Charles , Zage Peter E. , Zeng Lizhi , Zweidler-McKay Patrick A.
Published: April 2023

Supplementary Fig. S3 from Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Supplementary Fig. S1 from Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells
Authors: Zinner Ralph G. , Barrett Brittany L. , Popova Elmira , Damien Paul , Volgin Andrei Y. , Gelovani Juri G. , Lotan Reuben , Tran Hai T. , Pisano Claudio , Mills Gordon B. , Mao Li , Hong Waun K. , Lippman Scott M. , Miller John H.
Published: April 2023

Supplementary Fig. S1 from Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells
Supplementary Data from mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities
Authors: Liu Hongfang , D'Andrade Petula , Fulmer-Smentek Stephanie , Lorenzi Philip , Kohn Kurt W. , Weinstein John N. , Pommier Yves , Reinhold William C.
Published: April 2023

Supplementary Data from mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities
Supplementary Figure 2 from The Antitumor Activity of Homoharringtonine against Human Mast Cells Harboring the KIT D816V Mutation
Authors: Jin Yanli , Lu Zhongzheng , Cao Kaiyuan , Zhu Yunhui , Chen Qi , Zhu Feng , Qian Chenchen , Pan Jingxuan
Published: April 2023

Supplementary Figure 2 from The Antitumor Activity of Homoharringtonine against Human Mast Cells Harboring the KIT D816V Mutation
Supplementary Figure from Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling
Authors: Bhatt Rupal S. , Wang Xiaoen , Zhang Liang , Collins Michael P. , Signoretti Sabina , Alsop David C. , Goldberg S. Nahum , Atkins Michael B. , Mier James W.
Published: April 2023

Supplementary Figure from Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling
Supplementary Figure 4 from Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer
Authors: Bisht Savita , Mizuma Masamichi , Feldmann Georg , Ottenhof Niki A. , Hong Seung-Mo , Pramanik Dipankar , Chenna Venugopal , Karikari Collins , Sharma Rajni , Goggins Michael G. , Rudek Michelle A. , Ravi Rajani , Maitra Amarnath , Maitra Anirban
Published: April 2023

Supplementary Figure 4 from Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer
Supplementary Fig. S4 from Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines
Authors: Eguchi Tomohiro , Itadani Hiraku , Shimomura Toshiyasu , Kawanishi Nobuhiko , Hirai Hiroshi , Kotani Hidehito
Published: April 2023

Supplementary Fig. S4 from Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines
Analysis Methods Supplement from Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles
Authors: Gruvberger-Saal Sofia K. , Edén Patrik , Ringnér Markus , Baldetorp Bo , Chebil Gunilla , Borg Åke , Fernö Mårten , Peterson Carsten , Meltzer Paul S.
Published: April 2023

Analysis + 1 Figure and 3 Tables
Supplementary Figure 3 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
Authors: Coxon Angela , Bready James , Min Hosung , Kaufman Stephen , Leal Juan , Yu Dongyin , Lee Tani Ann , Sun Ji-Rong , Estrada Juan , Bolon Brad , McCabe James , Wang Ling , Rex Karen , Caenepeel Sean , Hughes Paul , Cordover David , Kim Haejin , Han Seog Joon , Michaels Mark L. , Hsu Eric , Shimamoto Grant , Cattley Russell , Hurh Eunju , Nguyen Linh , Wang Shao Xiong , Ndifor Anthony , Hayward Isaac J. , Falcón Beverly L. , McDonald Donald M. , Li Luke , Boone Tom , Kendall Richard , Radinsky Robert , Oliner Jonathan D.
Published: April 2023

Supplementary Figure 3 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
Authors: Coxon Angela , Bready James , Min Hosung , Kaufman Stephen , Leal Juan , Yu Dongyin , Lee Tani Ann , Sun Ji-Rong , Estrada Juan , Bolon Brad , McCabe James , Wang Ling , Rex Karen , Caenepeel Sean , Hughes Paul , Cordover David , Kim Haejin , Han Seog Joon , Michaels Mark L. , Hsu Eric , Shimamoto Grant , Cattley Russell , Hurh Eunju , Nguyen Linh , Wang Shao Xiong , Ndifor Anthony , Hayward Isaac J. , Falcón Beverly L. , McDonald Donald M. , Li Luke , Boone Tom , Kendall Richard , Radinsky Robert , Oliner Jonathan D.
Published: April 2023

Supplementary Figure 1 from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody
Supplementary Table 1 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Authors: Huang R. Stephanie , Duan Shiwei , Kistner Emily O. , Hartford Christine M. , Dolan M. Eileen
Published: April 2023

PDF file - 172K
Supplementary Fig. S5 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Authors: Huang R. Stephanie , Duan Shiwei , Kistner Emily O. , Hartford Christine M. , Dolan M. Eileen
Published: April 2023

Supplementary Fig. S5 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Supplementary Fig. S2 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Authors: Huang R. Stephanie , Duan Shiwei , Kistner Emily O. , Hartford Christine M. , Dolan M. Eileen
Published: April 2023

Supplementary Fig. S2 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Supplementary Figure 3 from Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species–Mediated Cellular Senescence
Authors: Lee Inkyoung , Park Chaehwa , Kang Won Ki
Published: April 2023

Supplementary Figure 3 from Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species–Mediated Cellular Senescence